Gold Nanotheranostics: Proof-of-Concept or Clinical Tool?

被引:89
|
作者
Pedrosa, Pedro [1 ]
Vinhas, Raquel [1 ]
Fernandes, Alexandra [1 ]
Baptista, Pedro V. [1 ]
机构
[1] UCIBIO, Dept Life Sci, Fac Ciencias & Tecnol, P-2829516 Caparica, Portugal
关键词
nanotheranostics; diagnostics; targeted therapy; cancer; gold nanoparticles; precision medicine; theranostics; PEGYLATED LIPOSOMAL DOXORUBICIN; IN-VIVO; PHOTOTHERMAL THERAPY; CANCER-CELLS; MULTIFUNCTIONAL NANOPARTICLES; INORGANIC NANOPARTICLES; PHOTODYNAMIC THERAPY; THERANOSTIC AGENTS; TARGETED DELIVERY; CELLULAR UPTAKE;
D O I
10.3390/nano5041853
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Nanoparticles have been making their way in biomedical applications and personalized medicine, allowing for the coupling of diagnostics and therapeutics into a single nanomaterial-nanotheranostics. Gold nanoparticles, in particular, have unique features that make them excellent nanomaterials for theranostics, enabling the integration of targeting, imaging and therapeutics in a single platform, with proven applicability in the management of heterogeneous diseases, such as cancer. In this review, we focus on gold nanoparticle-based theranostics at the lab bench, through pre-clinical and clinical stages. With few products facing clinical trials, much remains to be done to effectively assess the real benefits of nanotheranostics at the clinical level. Hence, we also discuss the efforts currently being made to translate nanotheranostics into the market, as well as their commercial impact.
引用
收藏
页码:1853 / 1879
页数:27
相关论文
共 50 条
  • [1] Blockgraph Proof-of-Concept
    Cordova, David A. M.
    Velloso, Pedro B.
    Guerre, Alexandre
    Nguyen, Thi-Mai-Trang
    Pujolle, Guy
    Alagha, Khaldoun
    Dua, Guillaume
    PROCEEDINGS OF THE 2021 SIGCOMM 2021 POSTER AND DEMO SESSIONS, SIGCOMM 2021 DEMOS AND POSTERS, 2024, : 82 - 84
  • [2] Enhancing Patient Care in Radiotherapy: Proof-of-Concept of a Monitoring Tool
    Beldjoudi, Guillaume
    Eugene, Remi
    Gregoire, Vincent
    Tanguy, Ronan
    TECHNOLOGIES, 2024, 12 (04)
  • [3] A cluster process monitoring tool for intrusion detection: Proof-of-concept
    Yurcik, W
    Meng, X
    Koenig, GA
    LCN 2004: 29TH ANNUAL IEEE INTERNATIONAL CONFERENCE ON LOCAL COMPUTER NETWORKS, PROCEEDINGS, 2004, : 427 - 428
  • [4] Opportunities and pitfalls in clinical proof-of-concept: principles and examples
    Chen, Chao
    DRUG DISCOVERY TODAY, 2018, 23 (04) : 776 - 787
  • [5] Anesthetic Cardioprotection in Clinical Practice From Proof-of-Concept to Clinical Applications
    Zaugg, Michael
    Lucchinetti, Eliana
    Behmanesh, Saeid
    Clanachan, Alexander S.
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (36) : 5706 - 5726
  • [6] Formal Simulation and Visualisation of Hybrid Programs An Extension of a Proof-of-Concept Tool
    Mendes, Pedro
    Correia, Ricardo
    Neves, Renato
    Proenca, Jose
    ELECTRONIC PROCEEDINGS IN THEORETICAL COMPUTER SCIENCE, 2024, (411):
  • [7] A novel clinical applicable bed-side tool for assessing conditioning pain modulation: proof-of-concept
    Arendt-Nielsen, Lars
    Larsen, Jesper
    Rasmussen, Stine
    Krogh, Malene
    Borg, Laura
    Madeleine, Pascal
    SCANDINAVIAN JOURNAL OF PAIN, 2020, 20 (04) : 801 - 807
  • [8] Elephants, Parkinson's Disease, and Proof-of-Concept Clinical Trials
    Cedarbaum, Jesse M.
    MOVEMENT DISORDERS, 2018, 33 (05) : 697 - 700
  • [9] From clinical proof-of-concept to commercialization of CAR T cells
    Calmels, Boris
    Mfarrej, Bechara
    Chabannon, Christian
    DRUG DISCOVERY TODAY, 2018, 23 (04) : 758 - 762
  • [10] Immuno-PET: Design options and clinical proof-of-concept
    Lugat, Alexandre
    Bailly, Clement
    Cherel, Michel
    Rousseau, Caroline
    Kraeber-Bodere, Francoise
    Bodet-Milin, Caroline
    Bourgeois, Mickael
    FRONTIERS IN MEDICINE, 2022, 9